Direxion Daily AMD Bull 2X Shares (NASDAQ: AMUU)

Últimas noticias sobre Direxion Daily AMD Bull 2X Shares (NASDAQ:AMUU)

The Fund, under normal circumstances, invests at least 80% of its net assets (plus any borrowings for investment purposes) in the securities of AMD and financial instruments, such as swap agreements and options, that, in combination, provide 2X daily leveraged exposure to AMD, consistent with the Funds investment objective. The financial instrument in which the Fund most commonly invests is swap agreements which are intended to produce economically leveraged investment results.

Dreyfus Trsy Prime Cash Mgmt - In 0 -

Gs Financial Square Treasury Instruments Fund

Dreyfus Govt Cash Man Ins

Goldman Sachs Fin Gov 465 Institut

Advanced Micro Devices

Direxion Daily AMD Bull 2X Shares ETF

Equities

Large Cap

News

Guidance

Asset Sales

Movers

AMUU

GAMR

SANM

AMD baja 1,6 % tras vender infraestructura de centros de datos a Sanmina. El acuerdo incluye efectivo, acciones y alianza estratégica.

AMD cae tras vender unidad de centros de datos a Sanmina

Long Ideas

Short Ideas

Specialty ETFs

Tech

Trading Ideas

ETFs

AMDD

AVGO

NVDA

Direxion lanza ETF apalancados para AMD: AMUU y AMDD. ¿Son una oportunidad para traders o un riesgo excesivo?

Nuevos ETF apalancados de AMD: ¿Oportunidad para traders o riesgo elevado?

Direxion Daily AMD Bull 2X Shares

<a href="https://x.com/DonaldJTrumpJr/status/1929965961341247842" title="https://x.com/DonaldJTrumpJr/status/1929965961341247842">https://x.com/DonaldJTrumpJr/status/1929965961341247842</a>

$TRUMP

Donald Trump Jr. Posts On X "The Trump Organization has zero involvement with this wallet product. @EricTrump and I know nothing about it. Stay tuned—World Liberty Financial @worldlibertyfi, which we have been working tirelessly on, will be launching our official wallet soon."

<a href="https://x.com/erictrump/status/1929966635445576103?s=46&amp;t=dtUiyC3dUs5yGRgT9qYHWg">https://x.com/erictrump/status/1929966635445576103?s=46&amp;t=dtUiyC3dUs5yGRgT9qYHWg</a>

General

Eric Trump Posts On X "I run @Trump and I know nothing about this project! @worldlibertyfi $Trump @AmericanBTC"

WIIM

RENB

RENB stock has given up its prior gain. Renovaro shares were trading higher after the company announced its subsidiary, BioSymetrics, received a Notice of Allowance from the United States Patent and Trademark Office for a new patent application titled "Methods, Systems, and Frameworks for Unbiased Data in Drug Discovery Predictions"

CEG stock has given up its prior gain. Constellation Energy shares were trading higher after the company announced it signed a 20-year nuclear power deal with Meta.

CoreWeave Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWV#NASDAQ">CRWV</a>) shares are trading higher Tuesday, extending gains after the company entered into a major long-term <a href="https://www.benzinga.com/trading-ideas/movers/25/06/45745818/applied-digital-stock-continues-to-climb-whats-going-on">infrastructure agreement with</a> Applied Digital Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>).
What To Know: The deal, announced on Monday, involves two 15-year lease agreements through which Applied Digital will provide 250 megawatts of critical IT load to support CoreWeave's AI and high-performance computing operations at a data center campus in North Dakota.
The agreement includes an option for CoreWeave to expand its presence at the facility with an additional 150 megawatts of IT load, potentially raising the total commitment to 400 megawatts. Applied Digital projects that it will generate approximately $7 billion in revenue from the contracts over the duration of the leases.
The site's first 100-megawatt capacity is expected to be operational by the fourth quarter of 2025, with an additional 150-megawatt phase scheduled for mid-2026. A third expansion phase, which would raise the facility's total load to 400 megawatts, is currently in planning and would be ready in 2027 if CoreWeave exercises its option.
The move signals CoreWeave's ongoing expansion as a key infrastructure provider in the rapidly growing AI computing market. The company specializes in delivering GPU-accelerated compute for AI workloads and the Applied Digital partnership is viewed as a major step in scaling its operational footprint.
Investor enthusiasm around the deal helped drive a sharp rally in CoreWeave's stock price as traders priced in the potential long-term value of the agreement amid rising demand for AI infrastructure. Applied Digital shares also surged <a href="https://www.benzinga.com/trading-ideas/movers/25/06/45721501/applied-digital-stock-surges-on-ai-data-center-deal-with-coreweave-what-you-need-to-know">more than 45%</a> on Monday following the news, reflecting positive sentiment throughout the AI infrastructure sector.
CRWV Price Action: CoreWeave shares were up 23.5% at $148.49 at the time of publication Tuesday, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="EXCLUSIVE: May's 20 Most-Searched Tickers On Benzinga Pro — Where Do Apple, Palantir, CoreWeave, Nvidia Rank? 
">EXCLUSIVE: May&#8217;s 20 Most-Searched Tickers On Benzinga Pro — Where Do Apple, Palantir, CoreWeave, Nvidia Rank? </a></li>
</ul>
Image via Shutterstock.

APLD

CRWV

CoreWeave Stock Hits New Highs: What's Going On?

As beer consumption dips and consumers search for lighter ways to unwind, hemp-derived THC beverages are carving out a serious niche in the U.S. market. For Tilray Brands Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>), one of the world's largest cannabis companies and a top craft beer player in the U.S., the rise of weed drinks isn't just a trend; it's a business strategy.
"We believe hemp beverages are just one more choice for adults looking to relax and unwind," Sam Garfinkel, senior vice president of commercial operations and strategy for Tilray Wellness, told Benzinga. "That concept shapes everything from formula development to our retailer strategy."
<h2 class="wp-block-heading">Tilray's Craft Beer Advantage</h2>
Tilray's deep bench in the alcohol world, including ownership of brands like SweetWater, Shock Top and Blue Point, is more than a diversification play. It gives the company a distribution and R&amp;D infrastructure few cannabis brands can match.
"We're fortunate to have a vast network of distributors, wholesalers, legal/regulatory experts, and food scientists," said Garfinkel. "That helps us get to market with breakthrough brands like Happy Flower and Fizzy Jane."
<h2 class="wp-block-heading">Formulation Challenges And Flavor Opportunities</h2>
Unlike alcohol, low-dose THC doesn't bring much flavor of its own, but Tilray sees that as a creative opportunity.
"Herbal ingredients actually complement the subtle hemp flavor nicely," Garfinkel noted. "We've just begun playing with that idea, and are excited for consumers to try our new Happy Flower Mojito this summer."
<h2 class="wp-block-heading">Scaling Consistency And Safety</h2>
Cannabis beverage brands often struggle with consistency and flavor stability, especially at a national scale. Tilray believes its infrastructure gives it an edge.
"One of our greatest capabilities is our extensive quality, testing and regulatory infrastructure," Garfinkel said. "While we're nimble enough to innovate quickly, we still have all the protocols and standards of a much larger organization."
<h2 class="wp-block-heading">Segmenting Like The Alcohol World</h2>
Rather than treat all THC drinkers the same, Tilray's beverage pipeline mirrors the segmentation strategies long used in the beer and wine markets.
"Some consumers are looking for a full-flavor cocktail-style beverage, which we address through our Happy Flower brand, while others are more focused on calories, which we deliver on with Fizzy Jane," said Garfinkel. "We're really just scratching the surface, but our focus will be on driving category incrementality as we address different segments of the market."
<h2 class="wp-block-heading">THC Drinks As The Fourth Pillar</h2>
Instead of replacing alcohol, Tilray sees hemp-derived THC drinks as something new entirely.
"Our research indicates that THC Beverage is highly incremental to beer, wine and spirits consumption," Garfinkel explained. "It presents an exciting opportunity for Tilray to develop an emerging category while still innovating for our craft beer and spirits consumers. We believe that THC Beverage will be a new pillar of adult beverage consumption over time."
<h2 class="wp-block-heading">The Competition: Big Tobacco Enters The Chat</h2>
While Tilray leans on alcohol expertise, companies like Organigram Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OGI#NASDAQ">OGI</a>), backed by British American Tobacco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BTI#NYSE">BTI</a>), are also entering the U.S. THC beverage market. Organigram has done so via its Collective Project brand, now sold in 10 states.
Asked about the competitive landscape, Garfinkel highlighted Tilray's ability to bridge all sides of the industry.
"With expertise in cannabis, BevAlc and hemp-based food and beverages, Tilray has a right to win in the hemp-derived Delta-9 THC beverage category," he said. "It is a competitive landscape, but Tilray's unique infrastructure and portfolio was crafted to take advantage of this very moment."
He added that Tilray is working with organizations like the Coalition for Adult Beverage Alternatives (CABA) to help create safety and quality standards for the entire category.
<h2 class="wp-block-heading">Looking Ahead</h2>
With recent data showing alcohol sales declining in regions that legalized cannabis and 60% of consumers now reporting they use cannabis to reduce alcohol intake, Tilray's push into hemp-derived THC drinks could be arriving at just the right time. Whether cannabis beverages become a new mainstream pillar or a profitable niche, one thing is certain: this isn't just a side hustle for the cannabis industry anymore. It's a serious bet on how the next generation chooses to relax.
Photo: Shutterstock

Cannabis

Exclusives

TLRY

THC Drinks Aren't The New Beer, They're Something Else, Says Tilray

AZEK

AZEK Co Says HSR Act Waiting Period For James Hardie Deal Expired As Of June 2, 2025

<a href="https://www.bloomberg.com/news/articles/2025-06-03/texas-stock-exchange-stands-by-2026-debut-as-nyse-nasdaq-circle?srnd=homepage-americas">https://www.bloomberg.com/news/articles/2025-06-03/texas-stock-exchange-stands-by-2026-debut-as-nyse-nasdaq-circle?srnd=homepage-americas</a>

'Texas Stock Exchange Stands by 2026 Debut'- Bloomberg

Micron Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) shares are trading higher Tuesday after the company announced it has started shipping qualification samples of its latest <a href="https://www.benzinga.com/pressreleases/25/06/g45745237/micron-ships-worlds-first-1-1-gamma-based-lpddr5x-enabling-rich-mobile-ai-experiences">low-power memory product</a>.
What To Know: The company&#8217;s new LPDDR5X memory is based on Micron&#8217;s 1-gamma node, which is one of the most advanced process technologies currently in development for DRAM. It is designed to support high-speed, low-power data handling in mobile devices, particularly those integrating artificial intelligence functions.
Micron said the memory is intended for use in flagship smartphones, where AI-driven features like image recognition, language processing and on-device machine learning require faster and more efficient memory. By beginning the sampling process, Micron is signaling that the product is nearing commercial readiness, allowing phone makers to begin validation and testing for potential inclusion in upcoming models.
The announcement comes as AI features are becoming increasingly prevalent in premium consumer devices, and memory performance remains a key bottleneck. The 1-gamma node offers improvements in density, speed and power efficiency, which are critical for battery-powered devices. The market is watching closely to see whether smartphone manufacturers will ramp up production volumes in the second half of 2025 given mixed signals on global demand.
Micron's AI-focused memory adds to ongoing momentum in the semiconductor sector, where companies are racing to meet the technical demands of AI applications across consumer, enterprise and industrial markets. For Micron, the LPDDR5X update serves to strengthen its position in the mobile segment, though broader market conditions and adoption timelines will determine how significantly this product contributes to near-term revenue.
MU Price Action: Micron shares were up 3.55% at $101.67 at the time of publication Tuesday, according to<a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2"> Benzinga Pro.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="EXCLUSIVE: May's 20 Most-Searched Tickers On Benzinga Pro — Where Do Apple, Palantir, CoreWeave, Nvidia Rank? 
">EXCLUSIVE: May&#8217;s 20 Most-Searched Tickers On Benzinga Pro — Where Do Apple, Palantir, CoreWeave, Nvidia Rank? </a></li>
</ul>
Image via Shutterstock.

Micron Stock Is Rising Tuesday: Here's Why

Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) shared data from several <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">cancer studies</a> at the 2025 American Society of Clinical Oncology (ASCO) annual meeting on Tuesday.
Here&#8217;s that the New Brunswick, New Jersey-based company released.
<h3 class="wp-block-heading">Phase 3 AMPLITUDE Study</h3>
Johnson &amp; Johnson released promising Phase 3 results from the AMPLITUDE study evaluating niraparib combined with abiraterone acetate plus prednisone (AAP) in metastatic castration-sensitive prostate cancer (mCSPC) patients with homologous recombination repair (HRR) genetic alterations, including BRCA mutations.
Key findings:
<ul class="wp-block-list">
<li>The study met its primary endpoint of radiographic progression-free survival (rPFS) among 696 patients.</li>
<li>Patients with BRCA mutations (n=191) saw the strongest benefit: 
<ul class="wp-block-list">
<li>Median rPFS was not reached vs. 26 months for placebo group</li>
<li>48% reduced risk of radiographic progression or death</li>
</ul>
</li>
<li>All HRR-altered patients also benefited: 
<ul class="wp-block-list">
<li>Median rPFS not reached vs. 29.5 months for placebo</li>
<li>37% reduced risk of progression or death</li>
</ul>
</li>
<li>Symptomatic progression was significantly reduced: 
<ul class="wp-block-list">
<li>56% reduction in BRCA patients</li>
<li>50% reduction in HRR patients</li>
</ul>
</li>
<li>Early overall survival (OS) data shows a positive trend: 
<ul class="wp-block-list">
<li>25% reduced risk of death in BRCA patients</li>
<li>21% reduction in HRR patients</li>
<li>OS data still maturing</li>
</ul>
</li>
</ul>
In summary, the combination therapy significantly delays disease progression and shows encouraging early signs of extending survival in genetically selected mCSPC patients.
<h3 class="wp-block-heading">JNJ-79635322 Phase 1 Study</h3>
Johnson &amp; Johnson released initial Phase 1 results of JNJ-79635322 for relapsed or refractory multiple myeloma.
The overall response rate (ORR) among the 36 patients who received the recommended phase 2 dose (RP2D) was 86.1%. In the 27 patients who were naive to BCMA and GPRC5D-directed therapies, the ORR <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/n45749276/early-results-from-johnson-johnsons-trispecific-antibody-show-promising-response-in-heavily-pretre" rel="noreferrer noopener">was 100% at the RP2D</a>.
<h3 class="wp-block-heading">Phase&nbsp;1b/2 CARTITUDE-1 Study</h3>
The company&nbsp;also revealed new long-term follow-up data from the Phase&nbsp;1b/2 CARTITUDE-1 study demonstrating 33% (n=32) of patients in the study (n=97) with relapsed or refractory multiple myeloma (RRMM) treated with CARVYKTI&nbsp;(ciltacabtagene autoleucel; cilta-cel) achieved PFS of five years or more with a single infusion and no maintenance or subsequent <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/n45749277/single-infusion-of-carvykti-ciltacabtagene-autoleucel-delivered-lasting-treatment-free-remissions-" rel="noreferrer noopener">anti-myeloma therapy</a>.
A subset of 12 patients who underwent serial evaluations at a single site remained minimal residual disease (MRD) negative and imaging negative throughout five years of post-treatment follow-up.
At a median follow-up of 61.3 months, the median OS was 60.7 months.
With longer follow-up, the safety profile in CARTITUDE-1 was consistent with the known safety profile of CARVYKTI, with no new safety signals observed.
There were two newly reported second primary malignancies (both solid tumors) and no new Parkinsonism events or cranial nerve palsies.
<h3 class="wp-block-heading">Phase 3 PERSEUS and Phase 3 CEPHEUS Studies</h3>
Johnson &amp; Johnson&nbsp;highlighted data from two studies of DARZALEX&nbsp;FASPRO (daratumumab and hyaluronidase-fihj)-based quadruplet regimen demonstrated deep and sustained MRD negativity rates and improved long-term progression-free survival (PFS) in patients with newly diagnosed multiple myeloma, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/n45749281/darzalex-faspro-daratumumab-and-hyaluronidase-fihj-based-regimen-shows-95-percent-progression-free" rel="noreferrer noopener">regardless of transplant status</a>.
<h3 class="wp-block-heading">Phase 3 PERSEUS Study</h3>
New analysis from the Phase 3 PERSEUS study shows the addition of DARZALEX&nbsp;FASPRO to bortezomib, lenalidomide and dexamethasone (D-VRd), followed by an investigational maintenance regimen of DARZALEX&nbsp;FASPRO with lenalidomide (D-R), led to improved and deepened rates of overall and sustained MRD negativity, defined as no cancer cells detected within 100,000 bone marrow cells for at least 24 months, compared to VRd induction and consolidation with R maintenance.
More than half of patients who received the DARZALEX&nbsp;FASPRO-based regimen achieved sustained MRD negativity for 24 or more months, and more than two-thirds of patients achieved sustained MRD negativity at 12 months, showing 95.3% PFS at 48 months.
<h3 class="wp-block-heading">Phase 3 CEPHEUS Study</h3>
The post-hoc analysis of the Phase 3 CEPHEUS study focused exclusively on transplant-ineligible patients, showing that DARZALEX&nbsp;FASPROto VRd significantly deepens response and prolongs PFS compared to VRd alone.
Data from the Phase 3 CEPHEUS study show 60% overall MRD negativity and improved PFS with DARZALEX FASPRO&nbsp;in transplant-ineligible newly diagnosed patients.
Price Action: JNJ stock is down 0.62% at $154.40 at the last check on Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/earnings/25/06/45745671/ferguson-stock-soars-on-strong-q3-growth-margin-gains-and-upbeat-guidance" target="_blank" rel="noreferrer noopener">Ferguson Stock Soars On Strong Q3 Growth, Margin Gains And Upbeat Guidance</a></li>
</ul>
Image: Shutterstock

Biotech

Health Care

Johnson & Johnson Highlights Multiple Blood Cancer Trial Data At ASCO Presentation

BofA Securities analyst Michael Feniger maintained a Buy rating on Caterpillar Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>) <a href="https://www.benzinga.com/quote/CAT/analyst-ratings" target="_blank" rel="noreferrer noopener">with a price forecast of $385</a>.
On Monday, the analyst held an event featuring Caterpillar Group President of Construction Industries Tony Fassino.
Feniger writes that despite ongoing uncertainties and his impression that tariff mitigation primarily involves cost flexibility rather than pricing adjustments, certain areas show promise amid macroeconomic volatility, including Infrastructure, Germany, Rest of the World markets and inventory levels.
Also Read: <a href="https://www.benzinga.com/25/05/45152082/b-of-a-on-caterpillars-tariffs-not-as-bad-as-anticipated-says-the-analyst" target="_blank" rel="noreferrer noopener">Caterpillar Tariff Impact Less Severe Than Anticipated: Analyst</a>
In particular, the analyst says that the U.S. economy remains &#8220;surprisingly durable,&#8221; with Infrastructure repeatedly cited as a bright spot, with ample funding and positive signals for future legislation.
Fassino observed customer resilience in adapting to challenges such as higher rates without pausing large projects, stressing that stability is key for pricing and volume, adds the analyst.
Caterpillar highlighted its flexible global footprint as a net U.S. exporter with optionality from other facilities. The company is implementing mitigation efforts such as tighter T&amp;E costs, but not primarily pricing.
The analyst writes he is more optimistic about the Rest of the World markets. While Europe remains soft, positive sentiment is emerging from Germany, fueled by infrastructure headlines.
In China, momentum feels genuine, with funding actively filtering in and projects underway, leading to observable double-digit growth from a recent low base. Notably, China&#8217;s excavator sales were up +18% year-over-year in April, adds the analyst.
Dealer inventories are at a comfortable three to four months, buffering tariff uncertainty, adds the analyst.
The analyst notes that Construction Industries&#8217; operating margins improved from roughly 10% in 2014 to about 24% in 2024, which stems from a better operating model, increased process efficiency and control, and strategic footprint changes.
The analyst expects Construction Industries&#8217; next cycle to emphasize higher services, building customer loyalty, leveraging predictive technology, and growing rentals.
CAT Price Action: Caterpillar shares are up 1.34% at $349.39 at publication on Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/05/45358732/machinery-stocks-surge-as-us-china-tariff-truce-eases-trade-pressures-whats-going-on" target="_blank" rel="noreferrer noopener">Machinery Stocks Surge As US–China Tariff Truce Eases Trade Pressures: What&#8217;s Going On?</a></li>
</ul>
Photo: Shuttersotck

Reiteration

Analyst Ratings

BofA Securities Stays Bullish On Caterpillar: 'Surprisingly Durable' US Economy, Global Momentum

BofA Securities analyst Brad Sills disclosed its <a href="https://www.benzinga.com/topic/software" target="_blank" rel="noreferrer noopener">software spending survey</a> on Tuesday.
Since his last survey in December, Sills&#8217; IT professionals&#8217; survey suggested that software spending growth intentions have come down a bit for the second half of 2025 and 2026. Software spending is expected to grow +9.9% for 2025, down 100 basis points from his December survey, and +10.8% for 2026, down 40 basis points. He said this aligns with management and channel commentary that changing macro policies are muddling the demand environment.
However, Sills&#8217; survey still suggests an improving backdrop in 2026, which is backed by channel feedback that pipelines for new software projects remain healthy.
The analyst noted that Data Analytics regained the top spot as a spending priority, trading places with Cloud Communications and Videoconferencing, which slipped to second place. Security held the third position, he said. Sills said other categories with notably higher spending expectations include observability and financials/ERP.
Sills noted that the lower-scoring categories were front-office applications such as CRM Sales, Marketing, and Support. He suggested that this could be due to firms evaluating AI priorities for front-office application projects.
For Analytics, Security, and Public Cloud, Sills noted the positive data supports his thesis for Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), Snowflake Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>), and Datadog Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDOG#NASDAQ">DDOG</a>), which are well positioned in these categories.
The analyst said Infrastructure and Back Office were the top software categories for AI investment (across Infrastructure, Back Office, Front Office, and Desktop Applications).
Back Office saw the largest increase since his year-end fiscal 2024 survey, he said. After LLMs, Workday Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDAY#NASDAQ">WDAY</a>) was the most selected, Sills noted.
The analyst noted that after LLMs, Salesforce Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) registered the highest number of front-office vendors in which respondents plan to invest in AI offerings.
Front office apps scored lower for the second consecutive survey, Sills noted.
The lower result reflects that firms remain in the discovery phase, as pricing models for agentic offerings such as Salesforce&#8217;s Agentforce and HubSpot Inc&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBS#NYSE">HUBS</a>) Breeze AI agents are evolving, per the analyst.
Sills noted that Amazon.Com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) AWS, Microsoft, and Alphabet Inc&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Google were the most frequently selected vendors for AI in infrastructure.
The analyst said Adobe Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>) remains the market leader in AI investments in desktop applications.
Hiring expectations are down for 2025, again, Sills noted, and recession expectations are fairly high. DOGE is impacting spending plans more so than tariffs, leading to a lower weighted average spending as per the survey.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/45746797/is-a-bond-market-crash-coming-jamie-dimon-blackrock-ray-dalio-and-others-sound-the-alarm">Is A Bond-Market Crash Coming? Jamie Dimon, BlackRock, Ray Dalio And Others Sound The Alarm</a></li>
</ul>
Photo: Shutterstock

ADBE

AMZN

DDOG

GOOG

GOOGL

HUBS

MSFT

SNOW

WDAY

Rising AI, Analytics Budgets Could Lift Microsoft, Snowflake, Datadog

Shares of MARA Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MARA#NASDAQ">MARA</a>) are trading higher Tuesday after the company reported a sharp increase in Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45752589/mara-holdings-riot-platforms-cleanspark-shares-rise-following-bitcoin-production-updates-heres-how-the-miners-stacked-up-in-may">production for May</a>.
What To Know: The Bitcoin miner reported total production of 950 Bitcoin during the month, representing a 35% jump from April. MARA also earned a record 282 blocks, up 38% month-over-month, marking its best performance since the Bitcoin halving event in April 2024.
The production gains helped MARA grow its total Bitcoin holdings to 49,179 as of the end of May. The company confirmed it did not sell any of its Bitcoin during the month. CEO Fred Thiel attributed the record production to MARA's fully integrated tech stack and the performance of its self-owned MARA Pool, which outperformed the network average in block reward luck by over 10%.
The company emphasized the efficiency of running its own mining pool, which eliminates fees paid to external operators and allows it to retain full value from block rewards. Thiel added that MARA's strategy of becoming a vertically integrated digital energy and infrastructure company is intended to boost operational control and resilience amid economic uncertainty.
Investors responded positively to the operational update, which showed increases across key metrics including hashrate and average BTC produced per day. MARA's improved mining performance reflects strong execution as the company scales its infrastructure.
MARA Price Action: Mara Holdings shares were up 6.79% at $15.34 at the time of writing, according to<a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2"> Benzinga Pro.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="EXCLUSIVE: May's 20 Most-Searched Tickers On Benzinga Pro — Where Do Apple, Palantir, CoreWeave, Nvidia Rank? 
">EXCLUSIVE: May&#8217;s 20 Most-Searched Tickers On Benzinga Pro — Where Do Apple, Palantir, CoreWeave, Nvidia Rank? </a></li>
</ul>
Image via Shutterstock.

$BTC

MARA

MARA Holdings Shares Climb After Company Reports Bitcoin Production Metrics

Investors with a lot of money to spend have taken a bearish stance on Cameco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCJ#NYSE">CCJ</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with CCJ, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 23 uncommon options trades for Cameco.
This isn't normal.
The overall sentiment of these big-money traders is split between 39% bullish and 43%, bearish.
Out of all of the special options we uncovered, 4 are puts, for a total amount of $228,821, and 19 are calls, for a total amount of $1,021,531.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $50.0 to $75.0 for Cameco over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Cameco's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Cameco's significant trades, within a strike price range of $50.0 to $75.0, over the past month.
<h3>Cameco Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748973737_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CCJ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>07/18/25</td>
<td>$1.61</td>
<td>$1.4</td>
<td>$1.52</td>
<td>$65.00</td>
<td>$142.7K</td>
<td>5.3K</td>
<td>1.7K</td>
</tr>
<tr>
<td>CCJ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$0.66</td>
<td>$0.59</td>
<td>$0.65</td>
<td>$65.00</td>
<td>$135.2K</td>
<td>13.5K</td>
<td>3.2K</td>
</tr>
<tr>
<td>CCJ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$0.68</td>
<td>$0.61</td>
<td>$0.66</td>
<td>$65.00</td>
<td>$126.6K</td>
<td>13.5K</td>
<td>5.2K</td>
</tr>
<tr>
<td>CCJ</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/20/26</td>
<td>$14.55</td>
<td>$14.4</td>
<td>$14.4</td>
<td>$70.00</td>
<td>$102.2K</td>
<td>218</td>
<td>132</td>
</tr>
<tr>
<td>CCJ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$1.71</td>
<td>$1.6</td>
<td>$1.6</td>
<td>$65.00</td>
<td>$65.9K</td>
<td>5.3K</td>
<td>683</td>
</tr>
</tbody>
</table>

<h3>About Cameco</h3>
Cameco Corp is a provider of uranium needed to generate clean, reliable baseload electricity around the globe. one of those uranium producers. It has three reportable segments, Uranium, Fuel Services, and Westinghouse. It derives maximum revenue from the Westinghouse Segment. It has some projects namely; Millennium, Yeelirrie, Kintyre, and Exploration. The company operates in Canada, Kazakhstan, Germany, Australia, and the United States.
In light of the recent options history for Cameco, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Present Market Standing of Cameco</h3>
<ul>
<li>With a volume of 4,124,113, the price of CCJ is up 2.54% at $59.66. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 57 days.</li>
</ul>
<h3>Expert Opinions on Cameco</h3>
Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $65.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Reflecting concerns, an analyst from Goldman Sachs lowers its rating to Buy with a new price target of $65.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Cameco options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Options

Markets

Behind the Scenes of Cameco's Latest Options Trends

Financial giants have made a conspicuous bearish move on Moderna. Our analysis of options history for Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) revealed 20 unusual trades.
Delving into the details, we found 40% of traders were bullish, while 45% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $317,887, and 16 were calls, valued at $3,451,522.
<h3>What's The Price Target?</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $20.0 to $165.0 for Moderna during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
In terms of liquidity and interest, the mean open interest for Moderna options trades today is 5144.21 with a total volume of 54,586.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Moderna's big money trades within a strike price range of $20.0 to $165.0 over the last 30 days.
<h3>Moderna Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748973731_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$6.1</td>
<td>$6.0</td>
<td>$6.1</td>
<td>$30.00</td>
<td>$1.2M</td>
<td>4.4K</td>
<td>4.9K</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$6.15</td>
<td>$6.1</td>
<td>$6.1</td>
<td>$30.00</td>
<td>$822.8K</td>
<td>4.4K</td>
<td>8.9K</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$6.15</td>
<td>$6.1</td>
<td>$6.1</td>
<td>$30.00</td>
<td>$362.9K</td>
<td>4.4K</td>
<td>5.5K</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$6.2</td>
<td>$6.1</td>
<td>$6.15</td>
<td>$30.00</td>
<td>$255.2K</td>
<td>4.4K</td>
<td>9.7K</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/20/26</td>
<td>$5.4</td>
<td>$5.35</td>
<td>$5.35</td>
<td>$35.00</td>
<td>$146.5K</td>
<td>916</td>
<td>274</td>
</tr>
</tbody>
</table>

<h3>About Moderna</h3>
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Having examined the options trading patterns of Moderna, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Current Position of Moderna</h3>
<ul>
<li>With a volume of 8,516,196, the price of MRNA is up 3.81% at $28.08. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 58 days.</li>
</ul>
<h3>What The Experts Say On Moderna</h3>
In the last month, 1 experts released ratings on this stock with an average target price of $26.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from JP Morgan has decided to maintain their Underweight rating on Moderna, which currently sits at a price target of $26. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Moderna options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

MRNA

This Is What Whales Are Betting On Moderna

Financial giants have made a conspicuous bullish move on Costco Wholesale. Our analysis of options history for Costco Wholesale (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) revealed 50 unusual trades.
Delving into the details, we found 42% of traders were bullish, while 32% showed bearish tendencies. Out of all the trades we spotted, 12 were puts, with a value of $1,128,843, and 38 were calls, valued at $3,395,853.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $440.0 to $1160.0 for Costco Wholesale over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Costco Wholesale's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Costco Wholesale's whale activity within a strike price range from $440.0 to $1160.0 in the last 30 days. 
<h3>Costco Wholesale Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748973726_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>COST</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$26.0</td>
<td>$25.1</td>
<td>$26.0</td>
<td>$920.00</td>
<td>$543.4K</td>
<td>879</td>
<td align="right">214</td>
</tr>
<tr>
<td>COST</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$93.2</td>
<td>$91.75</td>
<td>$91.75</td>
<td>$1055.00</td>
<td>$495.4K</td>
<td>67</td>
<td align="right">54</td>
</tr>
<tr>
<td>COST</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$130.0</td>
<td>$126.8</td>
<td>$130.0</td>
<td>$1060.00</td>
<td>$390.0K</td>
<td>314</td>
<td align="right">30</td>
</tr>
<tr>
<td>COST</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$18.3</td>
<td>$17.7</td>
<td>$17.7</td>
<td>$1050.00</td>
<td>$354.0K</td>
<td>748</td>
<td align="right">343</td>
</tr>
<tr>
<td>COST</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/06/25</td>
<td>$16.2</td>
<td>$15.9</td>
<td>$16.2</td>
<td>$1050.00</td>
<td>$285.1K</td>
<td>1.7K</td>
<td align="right">278</td>
</tr>
</tbody>
</table>

<h3>About Costco Wholesale</h3>
Costco operates a membership-based, no-frills retail model predicated on offering a select product assortment in bulk quantities at bargain prices. The firm avoids maintaining costly product displays by keeping inventory on pallets and limits distribution expenses by storing its inventory at point of sale in the warehouse. Given its frugal cost structure, the firm is able to price its merchandise below that of competing retailers, driving high sales volume per warehouse and generating strong profits on thin margins. Costco operates over 600 warehouses in the United States and has over 60% share in the domestic warehouse club industry. Internationally, Costco operates about 280 warehouses, primarily in Canada, Mexico, Japan, and the UK.
Having examined the options trading patterns of Costco Wholesale, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Costco Wholesale's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 1,170,863, the COST's price is down by -0.37%, now at $1052.91. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 114 days.</li>
</ul>
<h3>Expert Opinions on Costco Wholesale</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $1115.4.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Telsey Advisory Group has decided to maintain their Outperform rating on Costco Wholesale, which currently sits at a price target of $1100. 
&#x2A; An analyst from Morgan Stanley has decided to maintain their Overweight rating on Costco Wholesale, which currently sits at a price target of $1225. 
&#x2A; Consistent in their evaluation, an analyst from Loop Capital keeps a Buy rating on Costco Wholesale with a target price of $1110. 
&#x2A; Maintaining their stance, an analyst from Telsey Advisory Group continues to hold a Outperform rating for Costco Wholesale, targeting a price of $1100. 
&#x2A; Maintaining their stance, an analyst from Truist Securities continues to hold a Hold rating for Costco Wholesale, targeting a price of $1042. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Costco Wholesale, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

COST

Decoding Costco Wholesale's Options Activity: What's the Big Picture?

Analysts' ratings for Braze (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRZE#NASDAQ">BRZE</a>) over the last quarter vary from bullish to bearish, as provided by 16 analysts.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">10</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">5</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $48.38, a high estimate of $68.00, and a low estimate of $38.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 7.48%. 
<img src="https://www.benzinga.com/files/images/story/2025/1748973668_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A comprehensive examination of how financial experts perceive Braze is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Vanvliet</td>
<td>Cantor Fitzgerald</td>
<td>Announces</td>
<td>Overweight</td>
<td>$45.00</td>
<td>-</td>
</tr>
<tr>
<td>Ryan Macwilliams</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$47.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$38.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Michael Berg</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$40.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Buy</td>
<td>$40.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Brian Peterson</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$48.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Tyler Radke</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$55.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>David Hynes</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$50.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Patrick Walravens</td>
<td>Citizens Capital Markets</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$68.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Michael Berg</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$55.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Parker Lane</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$50.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Scott Berg</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$50.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Buy</td>
<td>$50.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Michael Berg</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$50.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Brian Peterson</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$45.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Brett Huff</td>
<td>Stephens &amp; Co.</td>
<td>Announces</td>
<td>Overweight</td>
<td>$43.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Braze. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Braze compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Braze's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Braze's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BRZE/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Braze analyst ratings.</a>
<h2>Delving into Braze's Background</h2>
Braze Inc is a customer engagement platform that powers customer-centric interactions between consumers and brands. The company provides solutions for Retail &amp; E-commerce, Media &amp; Entertainment, Financial Services, and Travel &amp; Hospitality related industries. The company offers a single, vertically integrated platform that encompasses the various functionalities, or layers, required for modern customer engagement: data ingestion, classification, orchestration, personalization, and action, all of which is supported by Sage AI by Braze, its AI engine designed to power AI functionality across all layers of this stack. It generates majority of its revenue from the United States.
<h3>Braze's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Braze displayed positive results in 3M. As of 31 January, 2025, the company achieved a solid revenue growth rate of approximately 22.48%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -10.72%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Braze's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -3.69%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -2.01%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Braze's debt-to-equity ratio is below the industry average. With a ratio of 0.18, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>What Are Analyst Ratings?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BRZE

Beyond The Numbers: 16 Analysts Discuss Braze Stock

Ratings for Docusign (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOCU#NASDAQ">DOCU</a>) were provided by 16 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">8</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $97.81, a high estimate of $124.00, and a low estimate of $65.00. This current average has decreased by 2.25% from the previous average price target of $100.06. 
<img src="https://www.benzinga.com/files/images/story/2025/1748973661_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A clear picture of Docusign's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patrick Walravens</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$124.00</td>
<td>$124.00</td>
</tr>
<tr>
<td>Michael Turrin</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$65.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Patrick Walravens</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$124.00</td>
<td>$124.00</td>
</tr>
<tr>
<td>Karl Keirstead</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$85.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Patrick Walravens</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$124.00</td>
<td>$124.00</td>
</tr>
<tr>
<td>Josh Baer</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$92.00</td>
<td>$97.00</td>
</tr>
<tr>
<td>Brent Thill</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$105.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Tyler Radke</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$115.00</td>
<td>$113.00</td>
</tr>
<tr>
<td>Rishi Jaluria</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Patrick Walravens</td>
<td>Citizens Capital Markets</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$124.00</td>
<td>$124.00</td>
</tr>
<tr>
<td>Mark Murphy</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$81.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Karl Keirstead</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Michael Turrin</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Underweight</td>
<td>$73.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Daniel Ives</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$100.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Brad Sills</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$98.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Mark Murphy</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$75.00</td>
<td>$70.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Docusign. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Docusign compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Docusign's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Docusign's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/DOCU/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Docusign analyst ratings.</a>
<h2>Get to Know Docusign Better</h2>
Docusign offers Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its initial public offering in 2018.
<h3>Breaking Down Docusign's Financial Performance</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Docusign displayed positive results in 3M. As of 31 January, 2025, the company achieved a solid revenue growth rate of approximately 8.97%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Information Technology sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Docusign's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 10.76% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Docusign's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 4.18%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Docusign's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 2.15%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.06, Docusign adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: Simplified</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

DOCU

Analyst Expectations For Docusign's Future

5 analysts have expressed a variety of opinions on Groupon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRPN#NASDAQ">GRPN</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Groupon, presenting an average target of $20.4, a high estimate of $35.00, and a low estimate of $9.00. This upward trend is apparent, with the current average reflecting a 24.39% increase from the previous average price target of $16.40.
<img src="https://www.benzinga.com/files/images/story/2025/1748973649_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Groupon. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bobby Brooks</td>
<td>Northland Capital Markets</td>
<td>Raises</td>
<td>Outperform</td>
<td>$35.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Eric Sheridan</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Sell</td>
<td>$15.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Sean McGowan</td>
<td>Roth MKM</td>
<td>Raises</td>
<td>Buy</td>
<td>$24.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Edward Woo</td>
<td>Ascendiant Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$19.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Eric Sheridan</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Sell</td>
<td>$9.00</td>
<td>$8.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Groupon. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Groupon compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Groupon's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Groupon's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/GRPN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Groupon analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>About Groupon</h2>
Groupon Inc acts as the middleman between consumers and merchants, offering products and services at discounts via its online store. It offers consumers daily deals from local merchants. The company's operations are organized into two segments: North America and International. The company generates the majority of its revenue from North America. The company generates revenue from transactions during which the company generates commissions by selling goods or services on behalf of third-party merchants. Revenue also includes commissions the company earn when customers make purchases with retailers using digital coupons accessed through its digital properties.
<h3>Key Indicators: Groupon's Financial Health</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Groupon's revenue growth over a period of 3M has faced challenges. As of 31 March, 2025, the company experienced a revenue decline of approximately -4.79%. This indicates a decrease in the company's top-line earnings. When compared to others in the Consumer Discretionary sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 6.12%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Groupon's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 16.63%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.18%, the company showcases effective utilization of assets.
Debt Management: With a high debt-to-equity ratio of 5.56, Groupon faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>Analyst Ratings: What Are They?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GRPN

Demystifying Groupon: Insights From 5 Analyst Reviews

Across the recent three months, 9 analysts have shared their insights on Winnebago Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WGO#NYSE">WGO</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $46.22, a high estimate of $60.00, and a low estimate of $38.00. Highlighting a 15.46% decrease, the current average has fallen from the previous average price target of $54.67. 
<img src="https://www.benzinga.com/files/images/story/2025/1748973641_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of Winnebago Industries among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Swartz</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$40.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Eric Heath</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$40.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Michael Swartz</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$38.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Craig Kennison</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$38.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Michael Albanese</td>
<td>Benchmark</td>
<td>Lowers</td>
<td>Buy</td>
<td>$60.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Michael Swartz</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$50.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Tristan Thomas-Martin</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$60.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Brett Andress</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$47.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>James Hardiman</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$43.00</td>
<td>$51.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Winnebago Industries. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Winnebago Industries compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Winnebago Industries's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Winnebago Industries's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/WGO/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Winnebago Industries analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Winnebago Industries</h2>
Winnebago Industries manufactures Class A, B, and C motor homes along with towables, customized specialty vehicles, boats, and parts. Headquartered in Eden Prairie, Minnesota, Winnebago has been producing recreational vehicles since 1958. Revenue was nearly $3 billion in fiscal 2024. Winnebago expanded into towables in 2011 with the acquisition of SunnyBrook and acquired Grand Design in November 2016. Towables made up 83% of the firm's RV unit volume, up from 31% in fiscal 2016. The company's total RV unit volume was 38,796 in fiscal 2024. Winnebago expanded into boating in 2018 with the purchase of Chris-Craft, bought premium motor home maker Newmar in November 2019, and bought Barletta pontoon boats in August 2021. It also is developing electric and autonomous technology.
<h3>Winnebago Industries: Delving into Financials</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Decline in Revenue: Over the 3M period, Winnebago Industries faced challenges, resulting in a decline of approximately -11.85% in revenue growth as of 28 February, 2025. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Discretionary sector.
Net Margin: Winnebago Industries's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -0.06%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Winnebago Industries's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -0.03%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Winnebago Industries's ROA stands out, surpassing industry averages. With an impressive ROA of -0.02%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.53.
<h2>The Basics of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

Direxion Daily AMD Bull 2X Shares

Noticias

Últimas noticias sobre Direxion Daily AMD Bull 2X Shares (NASDAQ:AMUU)

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL